Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999
Blamey RW, Ellis IO, Pinder SE, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 43:1548-1555, 2007
NHS Publication No 58. NHS Cancer Screening Programmes and the Royal College of Pathologists, Sheffield, Last viewed 22 May 2009
Ellis IO, Pinder SE, Bobrow L, et al. Pathology reporting of breast disease. NHS Publication No 58. NHS Cancer Screening Programmes and the Royal College of Pathologists, Sheffield, 2005 http://www.cancerscreening.nhs.uk/ breastscreen/publications/nhsbsp58-low-resolution.pdf (Last viewed 22 May 2009)
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
Protocol for the examination of specimens from patients with invasive carcinoma of the breast
Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133:1515-1538, 2009
Wells CA ed, 4th edition. Eds: Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European Commission, Luxemburg
Wells CA (ed). Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis. 4th edition. Eds: Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European Commission, Luxemburg 2006, pp 219-311
American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007